{"filing":{"accession_number":"0001171843-26-005782","cik":"0001729214","ticker":"XRTX","company_name":"XORTX Therapeutics Inc.","form":"6-K","filing_date":"2026-08-28","report_date":"2026-08-28","primary_document":"f6k_082826.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1729214/000117184326005782/f6k_082826.htm"},"events":[{"id":30175,"run_id":27657,"accession_number":"0001171843-26-005782","anchor_item_number":"EX-99.1","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.85,"summary":"The press release announces XORTX's voluntary delisting from the TSX Venture Exchange, expected to take effect September 1, 2026. While framed as a cost-reduction measure, a delisting materially affects the registrant's listing status and investor access to trading venues. The disclosure also includes a corrective disclosure of US$240,000 in finder's fees related to the Vectus acquisition that were inadvertently omitted from the April 2026 announcement, which is a material accounting correction. The primary event is the delisting announcement.","company_name":"XORTX Therapeutics Inc.","ticker":"XRTX","filing_date":"2026-08-28","form":"6-K","submitted_at":null,"items":[{"id":32701,"accession_number":"0001171843-26-005782","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.85,"reasoning":"The press release announces XORTX's voluntary delisting from the TSX Venture Exchange, expected to take effect September 1, 2026. While framed as a cost-reduction measure, a delisting materially affects the registrant's listing status and investor access to trading venues. The disclosure also includes a corrective disclosure of US$240,000 in finder's fees related to the Vectus acquisition that were inadvertently omitted from the April 2026 announcement, which is a material accounting correction. The primary event is the delisting announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-28T11:01:58.793455+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32701,"accession_number":"0001171843-26-005782","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.85,"reasoning":"The press release announces XORTX's voluntary delisting from the TSX Venture Exchange, expected to take effect September 1, 2026. While framed as a cost-reduction measure, a delisting materially affects the registrant's listing status and investor access to trading venues. The disclosure also includes a corrective disclosure of US$240,000 in finder's fees related to the Vectus acquisition that were inadvertently omitted from the April 2026 announcement, which is a material accounting correction. The primary event is the delisting announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-28T11:01:58.793455+00:00","company_name":"XORTX Therapeutics Inc.","ticker":"XRTX","filing_date":"2026-08-28"}]}